How should stable coronary artery disease be managed  in the modern era?

Harper, Richard W; Briganti, Esther M; Forge, Brett H R

doi:10.5694/j.1326-5377.2008.tb01541.x

Topics

To the Editor: The editorial by Woollard and Newman1 discussing the best management of stable coronary artery disease is welcome and timely, but we believe their conclusions undervalue the benefits of optimal medical therapy.

1 Monash Medical Centre, Melbourne, VIC.
2 Epworth Hospital, Melbourne, VIC.
3 West Gippsland Healthcare Group, Warragul, VIC.

Correspondence: bforge@absoluterisk.com

1. Woollard KV, Newman MAJ. How should stable coronary artery disease be managed in the modern era [editorial]? Med J Aust 2007; 187: 140-141. <MJA full text>
2. Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007; 115: 1082-1089.
3. Boden WE, O’Rouke RA, Teo KK, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516.
4. Pitt B, Waters D, Brown WV, et al; Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-76.

Online responses are no longer available. Please refer to our instructions for authors page for more information.